Immunohematological finding anticipates refractoriness to treatment with daratumumab in a patient with multiple mieloma
Vol. 22 No. 2 (2018), Clinical case
Vol. 22 No. 2 (2018)

Immunohematological finding anticipates refractoriness to treatment with daratumumab in a patient with multiple mieloma

Clinical case
Published 2019-01-15
K Andrade Vera
Servicio de Medicina Transfusional e Inmunohematología
L Fischman
Servicio de Hematología, Sanatorio Mater Dei, Ciudad Autónoma de Buenos Aires, República Argentina
G Bambés
Servicio de Medicina Transfusional e Inmunohematología Sanatorio Mater Dei, Ciudad Autónoma de Buenos Aires, República Argentina
S Bartolomeo
Servicio de Medicina Transfusional e Inmunohematología Sanatorio Mater Dei, Ciudad Autónoma de Buenos Aires, República Argentina
LA Carreras Vescio
Servicio de Medicina Transfusional e Inmunohematología Sanatorio Mater Dei, Ciudad Autónoma de Buenos Aires, República Argentina
ISSN 2250-8309 (versión en línea) - ISSN 0329-0379 (versión impresa)
pdf (Español (España))

Keywords

daratumumab, multiple myeloma, anti-CD38 immunohematologic interference, inhibitor antibodies

How to Cite

Andrade Vera, K., Fischman, L., Bambés, G., Bartolomeo, S., & Carreras Vescio, L. (2019). Immunohematological finding anticipates refractoriness to treatment with daratumumab in a patient with multiple mieloma. Journal of Hematology, 22(2), 185–187. Retrieved from https://revistahematologia.com.ar/index.php/Revista/article/view/25
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Daratumumab (DARA) is a human monoclonal antibody that targets CD38. It is used for the treatment of patients with refractory/relapse multiple myeloma. DARA interferes with immunohematological tests, causing positive agglutination reactions in indirect antiglobulin tests, antibody screening tests and crossmatches, from the beginning of the treatment until several months after finished.
We describe the case of a 65-years old patient with relapsed multiple myeloma treated with DARA. It was confirmed positivization in its immunohematological tests as planned, but evolving with a premature and unexpected negativization.
The patient was refractory to this treatment. This atypical immunohematological finding could be due to the development of anti-DARA antibodies.

pdf (Español (España))

References

1. Hannon JL, Caruk B, Clarke G. Serological findings related to treatment with a human monoclonal antibody (daratumumab) in patients with advanced plasma cell myeloma [abstract]. Transfusion. 2014;54:162A.
2. Hannon JL, Clarke G. Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma. Transfusion. 2015;55:2770.
3. Oostendorp M, Lammerts van Bueren JJ, Doshi P y col. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55:1555-62.
4. Chapuy CI, Aguad MD, Nicholson RT y col. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016;56:2964-2972.
5. European Medicines Agency. Darzalex, concentrate for solution for infusion: EU summary of product characteristics. 2017. http://www.ema.europa.eu.

All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar

Downloads

Download data is not yet available.